This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The emerging role and targetability of the TCA cycle in cancer metabolism
Protein & Cell Open Access 26 July 2017
-
TET proteins and the control of cytosine demethylation in cancer
Genome Medicine Open Access 29 January 2015
-
Driver mutations of cancer epigenomes
Protein & Cell Open Access 14 March 2014
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yen KE, Bittinger MA, Su SM, Fantin VR . (2010). Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29: 6409–6417.
Prensner JR, Chinnaiyan AM . (2011). Metabolism unhinged: IDH mutations in cancer. Nat Med 17: 291–293.
Chan N, Milosevic M, Bristow RG . (2007). Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 3: 329–341.
Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A et al. (2009). High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 69: 1091–1100.
Bristow RG, Hill RP . (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180–192.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765–773.
Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al. (2009). IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7–11.
Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al. (2009). Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125: 353–355.
Park SW, Chung NG, Han JY, Eom HS, Lee JY, Yoo NJ et al. (2009). Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer 125: 2485–2486.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Ghiam, A., Cairns, R., Thoms, J. et al. IDH mutation status in prostate cancer. Oncogene 31, 3826 (2012). https://doi.org/10.1038/onc.2011.546
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.546
This article is cited by
-
Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas
Purinergic Signalling (2024)
-
Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma
Journal of Cancer Research and Clinical Oncology (2023)
-
Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors
Pharmaceutical Chemistry Journal (2021)
-
The emerging role and targetability of the TCA cycle in cancer metabolism
Protein & Cell (2018)
-
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
BioDrugs (2017)